| Nome |
# |
|
PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?, file e3835322-ebe6-15e8-e053-a505fe0a3de9
|
179
|
|
The course of cancer related fatigue up to ten years in early breast cancer patients. What impact in clinical practice?, file e3835323-58ae-15e8-e053-a505fe0a3de9
|
161
|
|
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy. An italian, multicenter, randomized phase III trial, file e3835323-59a6-15e8-e053-a505fe0a3de9
|
136
|
|
MTOR cross-talk in cancer and potential for combination therapy, file e383531d-8541-15e8-e053-a505fe0a3de9
|
125
|
|
Impressive long-term response with pertuzumab and trastuzumab in HER2-positive breast cancer with brain metastasis, file e3835323-2e02-15e8-e053-a505fe0a3de9
|
122
|
|
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models, file e383531d-6b25-15e8-e053-a505fe0a3de9
|
121
|
|
Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC), file e3835323-58b4-15e8-e053-a505fe0a3de9
|
110
|
|
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer, file e3835323-3d55-15e8-e053-a505fe0a3de9
|
106
|
|
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program, file e3835322-eaa0-15e8-e053-a505fe0a3de9
|
105
|
|
Role of mTOR signaling in tumor microenvironment. An overview, file e383531e-851e-15e8-e053-a505fe0a3de9
|
104
|
|
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer, file e383531d-4a0b-15e8-e053-a505fe0a3de9
|
103
|
|
Metastatic pancreatic cancer. Is there a light at the end of the tunnel?, file e3835323-19a5-15e8-e053-a505fe0a3de9
|
101
|
|
Rankl/Rank/Opg system beyond bone remodeling. Involvement in breast cancer and clinical perspectives, file e3835322-ebea-15e8-e053-a505fe0a3de9
|
100
|
|
Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer. Clinical results and biological observations in taxane-pretreated patients, file e3835323-29b9-15e8-e053-a505fe0a3de9
|
100
|
|
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: Meta-analysis of randomized clinical trials, file e3835323-166c-15e8-e053-a505fe0a3de9
|
95
|
|
Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer. Meta-analysis of randomized trials, file e3835323-232a-15e8-e053-a505fe0a3de9
|
94
|
|
Activity of eribulin mesylate in brain metastasis from breast cancer. a stone in a pond?, file e3835323-5829-15e8-e053-a505fe0a3de9
|
94
|
|
Chordoma. Clinical characteristics, management and prognosis of a case series of 25 patients, file e3835323-1c3f-15e8-e053-a505fe0a3de9
|
93
|
|
First-line therapy in HER2 positive metastatic breast cancer. Is the mosaic fully completed or are we missing additional pieces?, file e3835323-29b6-15e8-e053-a505fe0a3de9
|
92
|
|
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors. an important role for mutations in minor clones, file e3835323-3ebf-15e8-e053-a505fe0a3de9
|
92
|
|
PTEN. Multiple Functions in Human Malignant Tumors, file e3835314-2db1-15e8-e053-a505fe0a3de9
|
91
|
|
Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer, file e383531d-6c58-15e8-e053-a505fe0a3de9
|
91
|
|
Brain metastases from solid tumors. Disease outcome according to type of treatment and therapeutic resources of the treating center, file e3835323-497c-15e8-e053-a505fe0a3de9
|
88
|
|
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients. Meta-regression analysis of randomized trials, file e3835323-45c2-15e8-e053-a505fe0a3de9
|
87
|
|
Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab, file e3835323-5b4a-15e8-e053-a505fe0a3de9
|
86
|
|
The withdrawal from oncogenetic counselling and testing for hereditary and familial breast and ovarian cancer. A descriptive study of an Italian sample, file e3835323-37b8-15e8-e053-a505fe0a3de9
|
85
|
|
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer. A comparison of different schedules and treatments, file e3835323-3d59-15e8-e053-a505fe0a3de9
|
85
|
|
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer. Efficacy in combination with hormonal therapy, file e3835323-0fee-15e8-e053-a505fe0a3de9
|
84
|
|
Subjective versus objective risk in genetic counseling for hereditary breast and/or ovarian cancers, file e3835323-2d29-15e8-e053-a505fe0a3de9
|
81
|
|
Targeting targeted agents. Open issues for clinical trial design, file e3835323-4778-15e8-e053-a505fe0a3de9
|
81
|
|
KRAS early testing. Consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an italian setting, file e3835323-1b57-15e8-e053-a505fe0a3de9
|
80
|
|
Eribulin in brain metastases of breast cancer. outcomes of the EBRAIM prospective observational trial, file e383532c-7e11-15e8-e053-a505fe0a3de9
|
73
|
|
Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study, file e3835323-0eca-15e8-e053-a505fe0a3de9
|
5
|
|
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials, file e3835322-ea9d-15e8-e053-a505fe0a3de9
|
4
|
|
First-line crizotinib versus chemotherapy in ALK-positive lung cancer, file e3835323-29bd-15e8-e053-a505fe0a3de9
|
4
|
|
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer. Meta-analytical estimation and implications for therapeutic strategies, file e3835323-55fb-15e8-e053-a505fe0a3de9
|
4
|
|
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients, file e3835323-58ab-15e8-e053-a505fe0a3de9
|
4
|
|
Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with anti tumor efficacy., file e3835311-c8c3-15e8-e053-a505fe0a3de9
|
3
|
|
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies, file e3835323-1c43-15e8-e053-a505fe0a3de9
|
3
|
|
In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy, file e3835323-3eb3-15e8-e053-a505fe0a3de9
|
3
|
|
Improved survival with vemurafenib in melanoma with BRAF V600E mutation, file e3835323-44a6-15e8-e053-a505fe0a3de9
|
3
|
|
Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients, file e3835323-4784-15e8-e053-a505fe0a3de9
|
3
|
|
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients. A pooled analysis of the MIG1 and GIM2 phase III studies, file e3835323-58b0-15e8-e053-a505fe0a3de9
|
3
|
|
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine, file e3835323-6051-15e8-e053-a505fe0a3de9
|
3
|
|
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies., file e3835311-e1d3-15e8-e053-a505fe0a3de9
|
2
|
|
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme, file e3835322-46ff-15e8-e053-a505fe0a3de9
|
2
|
|
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care, file e3835323-0fe8-15e8-e053-a505fe0a3de9
|
2
|
|
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer. Preliminary activity results of the MITO-2 phase III trial, file e3835323-1a8b-15e8-e053-a505fe0a3de9
|
2
|
|
Targeting bone metastatic cancer. Role of the mTOR pathway, file e3835323-29cc-15e8-e053-a505fe0a3de9
|
2
|
|
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis, file e3835323-2d20-15e8-e053-a505fe0a3de9
|
2
|
|
Pseudoprogression and MGMT status in glioblastoma patients. implications in clinical practice, file e3835323-37a8-15e8-e053-a505fe0a3de9
|
2
|
|
A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer, file e3835323-37b4-15e8-e053-a505fe0a3de9
|
2
|
|
Darbepoetin alfa and history of thromboembolic events, file e3835323-3908-15e8-e053-a505fe0a3de9
|
2
|
|
Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Meta-analysis of randomized trials, file e3835323-3aaf-15e8-e053-a505fe0a3de9
|
2
|
|
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer, file e3835323-41ee-15e8-e053-a505fe0a3de9
|
2
|
|
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers, file e3835323-477e-15e8-e053-a505fe0a3de9
|
2
|
|
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278), file e3835323-4782-15e8-e053-a505fe0a3de9
|
2
|
|
Taxanes as primary chemotherapy for early breast cancer. Meta-analysis of randomized trials, file e3835323-4788-15e8-e053-a505fe0a3de9
|
2
|
|
Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer, file e3835323-497e-15e8-e053-a505fe0a3de9
|
2
|
|
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial, file e3835323-4981-15e8-e053-a505fe0a3de9
|
2
|
|
Large randomized study of thymosin α 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma, file e3835323-4d86-15e8-e053-a505fe0a3de9
|
2
|
|
Fixed-dose-rate gemcitabine. A viable first-line treatment option for advanced pancreatic and biliary tract cancer, file e3835323-4d88-15e8-e053-a505fe0a3de9
|
2
|
|
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial, file e3835323-582d-15e8-e053-a505fe0a3de9
|
2
|
|
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET). 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial, file e3835323-5831-15e8-e053-a505fe0a3de9
|
2
|
|
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21). a double-blind, randomised, placebo-controlled, phase 3 trial, file e3835323-5837-15e8-e053-a505fe0a3de9
|
2
|
|
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy, file e3835323-599f-15e8-e053-a505fe0a3de9
|
2
|
|
Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?, file e3835323-5b46-15e8-e053-a505fe0a3de9
|
2
|
|
Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies, file e3835323-605c-15e8-e053-a505fe0a3de9
|
2
|
|
Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study, file 8a77f6e1-f19b-4dca-89ee-5b9f154082ae
|
1
|
|
Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations., file e3835311-53e3-15e8-e053-a505fe0a3de9
|
1
|
|
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort., file e3835313-0097-15e8-e053-a505fe0a3de9
|
1
|
|
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study, file e3835313-0287-15e8-e053-a505fe0a3de9
|
1
|
|
Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy. three-year follow-up of a randomized phase 3 trial, file e3835322-d787-15e8-e053-a505fe0a3de9
|
1
|
|
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer, file e3835323-0ecc-15e8-e053-a505fe0a3de9
|
1
|
|
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment. A meta-analysis, file e3835323-0fe5-15e8-e053-a505fe0a3de9
|
1
|
|
Everolimus plus exemestane in advanced breast cancer. Safety results of the BALLET study on patients previously treatedwithout and with chemotherapy in the metastatic setting, file e3835323-19a0-15e8-e053-a505fe0a3de9
|
1
|
|
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: An open-label, 2 × 2 factorial, randomised phase 3 trial, file e3835323-19a7-15e8-e053-a505fe0a3de9
|
1
|
|
Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas, file e3835323-19b7-15e8-e053-a505fe0a3de9
|
1
|
|
Adjuvant treatment for resected renal cell carcinoma. Are all strategies equally negative? Potential implications for trial design with targeted agents, file e3835323-1b5e-15e8-e053-a505fe0a3de9
|
1
|
|
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study, file e3835323-2808-15e8-e053-a505fe0a3de9
|
1
|
|
Nivolumab in previously untreated melanoma without BRAF mutation, file e3835323-29bf-15e8-e053-a505fe0a3de9
|
1
|
|
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis, file e3835323-29c1-15e8-e053-a505fe0a3de9
|
1
|
|
Palbociclib. efficacious but predictive biomarkers still needed, file e3835323-58b7-15e8-e053-a505fe0a3de9
|
1
|
|
Emerging pathways and future targets for the molecular therapy of pancreatic cancer, file e3835323-59a9-15e8-e053-a505fe0a3de9
|
1
|
|
Management and treatment of triple-negative breast cancer patients from the NEMESI study. An Italian experience, file e3835323-5b43-15e8-e053-a505fe0a3de9
|
1
|
|
Early recurrence risk: Aromatase inhibitors versus tamoxifen, file e3835323-604d-15e8-e053-a505fe0a3de9
|
1
|
|
Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer. Preliminary results of a feasibility-phase II study aimed at cardiotoxicity, file e3835323-6155-15e8-e053-a505fe0a3de9
|
1
|
| Totale |
3.354 |